Loading, Please wait ...

Please contact us if you would like to upgrade your account to include access to financial models

Please contact us if you would like to upgrade your account to include short term strategies for this stock.

QGEN.O

ISIN: NL0000240000
SEDOL: 2437907

Rating:

BUY

Target Price:

19.18 USD

Investment Horizon:

6 to 12 months
5th May 2009 View Report   Download

1Q 09 News Alert

Qiagen N.V. (Qiagen) reported modest y-o-y revenue growth in 1Q 09, in-line with our estimate. Adjusted1 operating margin fell short of our expectation in 1Q 09. Going forward, we believe Qiagen’s strategy to strengthen its position in the molecular diagnostic solutions market will positively benefit the company’s top-line performance. Furthermore, recent product launches in the Consumables segment are also expected to positively impact revenues in FY 2009....

16th Mar 2009 View Report   Download

4Q 08 & FY 2008 Update Report

Qiagen’s Digene HPV test is the first US Food and Drug Administration (FDA) approved and CE marked test for Human Papilloma Virus (HPV), which is linked as the second highest cause of female cancer mortality worldwide. The molecular diagnostic tests screening for HPV comprised approximately 50% of revenues derived from molecular diagnostic products in the Consumables segment during 4Q 08. We believe that Qiagen can gain a strong presence in this niche…

10th Feb 2009 View Report   Download

4Q 08 & FY 2008 News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Qiagen N.V. (Qiagen) reported modest y-o-y revenue growth in 4Q 08, falling marginally below our estimate. Adjusted1 operating margin exceeded our expectation in 4Q 08. Going forward, we believe Qiagen’s recent acquisitions will strengthen its position in the molecular diagnostic solutions market. Furthermore, the recent product launches in the Consumables…

2nd Dec 2008 View Report   Download

3Q 08 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

During 3Q 08, Qiagen N.V.’s (Qiagen) revenues experienced robust growth, in-line with our estimate. Revenues are expected to be driven by recurring sales of reagents, further augment by wider acceptance of new product launches from the Consumables segment, focusing on gene and protein function analysis and instruments, such as QIAsymphony and QIAexcel, going forward. However, we expect margins to o remain under pressure, primarily…

11th Nov 2008 View Report   Download

3Q 08 News Alert

CLICK VIEW REPORT TO READ FREE REPORT

Qiagen N.V. (Qiagen) reported robust y-o-y revenue growth in 3Q 08, in-line with our estimate. Adjusted1 operating margin exceeded our expectation, while adjusted net margin fell short of our estimate in 3Q 08. Going forward, we believe acquisition of the Biosystem business from Biotage will strengthen Qiagen’s position in the molecular diagnostic solutions market and expand its product offering in the Consumable business. Consequently…